Covered recipient · General Payments record
RALPH J HAUKE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$225.23
10 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $205.23 | 9 |
| Education | $20.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $52.99 | 2 |
| Verity Pharmaceuticals Inc. | $40.86 | 2 |
| E.R. Squibb & Sons, L.L.C. | $38.90 | 2 |
| PFIZER INC. | $36.25 | 2 |
| Dendreon Pharmaceuticals LLC | $36.23 | 1 |
| Aveo Pharmaceuticals, Inc. | $20.00 | 1 |
Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RALPH J HAUKE
NPI 1578511283 · CMS profile ID 297671
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
OMAHA, NE
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578511283?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
10 matching records · $225.23 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–10 of 10.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Aveo Pharmaceuticals, Inc. | $20.00 | 12/04/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143484724 | CMS |
| Verity Pharmaceuticals Inc. | $21.10 | 11/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080607422 | CMS |
| ABBVIE INC. | $21.18 | 10/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103892021 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.90 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101579847 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 09/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101579831 | CMS |
| PFIZER INC. | $16.74 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131359195 | CMS |
| Dendreon Pharmaceuticals LLC | $36.23 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149316916 | CMS |
| ABBVIE INC. | $31.81 | 07/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103892019 | CMS |
| PFIZER INC. | $19.51 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131307257 | CMS |
| Verity Pharmaceuticals Inc. | $19.76 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080607418 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $609.30 | 2 |
| PY2025 | Principal investigator | $1,167,738.55 | 292 |
| PY2024 | Principal investigator | $1,299,594.58 | 212 |
| PY2023 | Principal investigator | $2,735,258.21 | 252 |
| PY2022 | Recipient | $4,157.00 | 1 |
| PY2022 | Principal investigator | $1,567,591.67 | 137 |
| PY2021 | Principal investigator | $2,060,900.77 | 213 |
| PY2020 | Recipient | $705.81 | 1 |
| PY2020 | Principal investigator | $1,867,000.72 | 289 |
| PY2019 | Principal investigator | $1,377,455.65 | 354 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
354 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $441.60 | 12/30/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 691528945 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,131.20 | 12/18/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691478013 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,292.00 | 12/16/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691478017 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,375.00 | 12/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | No dispute reported | 06/30/2026 | 639760847 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547403 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547405 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547407 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547409 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547411 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547413 |
| Principal investigator 1 | Eisai Inc. | $580.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547421 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547423 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 12/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547429 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $46,246.88 | 12/13/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691528949 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $76.70 | 12/13/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691528955 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $21,652.48 | 12/13/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691530017 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $1,340.00 | 12/11/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | PCYC-1128-CA | No dispute reported | 06/30/2026 | 673092347 |
| Principal investigator 1 | Genentech, Inc. | $664.00 | 12/06/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 681100997 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $21,652.48 | 12/06/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691530019 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $568.35 | 12/02/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691528951 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $649.40 | 12/02/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB AS ADJUVANT THERAPY FOR SUBJECTS WITH LOCALIZED OR LOCALLY ADVANCED RCC FOLLOWING NEPHRECTOMY | No dispute reported | 06/30/2026 | 640707173 |
| Principal investigator 1 | Exelixis Inc. | $10,917.40 | 11/27/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687196527 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,388.80 | 11/22/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691479859 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,602.00 | 11/21/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 641393213 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,125.00 | 11/21/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639760829 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $34,685.16 | 11/18/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691516591 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 11/18/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691530013 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547395 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547397 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547399 |
| Principal investigator 1 | Eisai Inc. | $980.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547401 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547415 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547417 |
| Principal investigator 1 | Eisai Inc. | $2,134.00 | 11/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547419 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/15/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480427 |
| Principal investigator 1 | Incyte Corporation | $350.00 | 11/15/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480429 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $496.80 | 11/13/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | PCYC-1128-CA | No dispute reported | 06/30/2026 | 673092339 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $13,565.60 | 11/06/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691530009 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,000.00 | 11/05/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639760823 |
| Principal investigator 1 | Dynavax Technologies Corporation | $6,876.00 | 10/28/2019 | Non-covered Recipient Entity Oncology Hematology West | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 696041061 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,427.60 | 10/25/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691486039 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $261.30 | 10/18/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691479187 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $111.60 | 10/17/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 691476957 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $74.40 | 10/17/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691479191 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547355 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547357 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547359 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547361 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547389 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547391 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 10/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547393 |
| Principal investigator 1 | Incyte Corporation | $1,063.00 | 10/15/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480425 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $216.78 | 10/15/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691478819 |
| Principal investigator 1 | Exelixis Inc. | $221.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198593 |
| Principal investigator 1 | Exelixis Inc. | $1,495.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198599 |
| Principal investigator 1 | Exelixis Inc. | $5,850.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198603 |
| Principal investigator 1 | Exelixis Inc. | $65.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198607 |
| Principal investigator 1 | Exelixis Inc. | $12,500.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198609 |
| Principal investigator 1 | Exelixis Inc. | $1,500.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198613 |
| Principal investigator 1 | Exelixis Inc. | $260.00 | 10/10/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 687198619 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,292.00 | 10/04/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691482759 |
| Principal investigator 1 | Astellas Pharma Global Development | $5,127.00 | 09/26/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 641393205 |
| Principal investigator 1 | AstraZeneca AB | $53,193.26 | 09/26/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 684998251 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,246.80 | 09/25/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441067 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $135.74 | 09/24/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | No dispute reported | 06/30/2026 | 639760853 |
| Principal investigator 1 | Dynavax Technologies Corporation | $3,000.00 | 09/23/2019 | Non-covered Recipient Entity Oncology Hematology West | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 696041035 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,264.00 | 09/20/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every 2 Weeks. | No dispute reported | 06/30/2026 | 639760837 |
| Principal investigator 1 | PFIZER INC. | $23,865.04 | 09/17/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES | No dispute reported | 06/30/2026 | 671693953 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $614.20 | 09/16/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | No dispute reported | 06/30/2026 | 639760849 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 09/16/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441431 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547327 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547329 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547331 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547333 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547335 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547345 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547347 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547349 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547351 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547353 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547383 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 09/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $604.00 | 09/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255311 |
| Principal investigator 1 | Janssen Research & Development, LLC | $707.00 | 09/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255313 |
| Principal investigator 1 | Janssen Research & Development, LLC | $589.00 | 09/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $589.00 | 09/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255321 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $3,220.00 | 09/12/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | PCYC-1128-CA | No dispute reported | 06/30/2026 | 673092187 |
| Principal investigator 1 | Incyte Corporation | $42.75 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480387 |
| Principal investigator 1 | Incyte Corporation | $59.40 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480389 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480391 |
| Principal investigator 1 | Incyte Corporation | $14.25 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480393 |
| Principal investigator 1 | Incyte Corporation | $1.00 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480395 |
| Principal investigator 1 | Incyte Corporation | $17.55 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480397 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480399 |
| Principal investigator 1 | Incyte Corporation | $0.44 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480401 |
| Principal investigator 1 | Incyte Corporation | $25.07 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480403 |
| Principal investigator 1 | Incyte Corporation | $42.75 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480405 |
| Principal investigator 1 | Incyte Corporation | $42.75 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480407 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480409 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480411 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480413 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480415 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480417 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480419 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480421 |
| Principal investigator 1 | Incyte Corporation | $28.50 | 09/10/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480423 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $36.30 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691439959 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $14.06 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440421 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.45 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440495 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $11.40 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440599 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12.10 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440605 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12.10 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440609 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $31.50 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441227 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5.22 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441530 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $34.35 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441781 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $36.30 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441791 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $19.80 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691442097 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.40 | 09/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691442785 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $77.38 | 08/22/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691479195 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $244.10 | 08/19/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 691539739 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $225.50 | 08/17/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691478823 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,284.00 | 08/16/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441071 |
| Principal investigator 1 | Eisai Inc. | $580.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547337 |
| Principal investigator 1 | Eisai Inc. | $580.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547339 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547341 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547343 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547363 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547365 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547367 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547369 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547371 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547373 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547375 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547377 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547379 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547381 |
| Principal investigator 1 | Eisai Inc. | $85.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547387 |
| Principal investigator 1 | Eisai Inc. | $85.00 | 08/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $555.00 | 08/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $589.00 | 08/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255317 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,425.00 | 08/12/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441059 |
| Principal investigator 1 | PFIZER INC. | $7,500.00 | 08/06/2019 | Non-covered Recipient Entity US Oncology Research LLC | TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE | No dispute reported | 06/30/2026 | 671666655 |
| Principal investigator 1 | PFIZER INC. | $7,370.00 | 08/06/2019 | Non-covered Recipient Entity US Oncology Research LLC | TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE | No dispute reported | 06/30/2026 | 671666749 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $554.40 | 08/05/2019 | Non-covered Recipient Entity Us Oncology Reserch Llc | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | No dispute reported | 06/30/2026 | 629159893 |
| Principal investigator 1 | Astellas Pharma Global Development | $140.00 | 07/25/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 641393197 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4,444.00 | 07/24/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440985 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 07/17/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547313 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $32,478.72 | 07/17/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691432057 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $69,370.32 | 07/17/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691443575 |
| Principal investigator 1 | Exelixis Inc. | $1,950.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199581 |
| Principal investigator 1 | Exelixis Inc. | $130.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199585 |
| Principal investigator 1 | Exelixis Inc. | $910.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199587 |
| Principal investigator 1 | Exelixis Inc. | $7,500.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199589 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199611 |
| Principal investigator 1 | Exelixis Inc. | $390.00 | 07/16/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 687199613 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 07/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440968 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $500.00 | 07/11/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | PCYC-1128-CA | No dispute reported | 06/30/2026 | 673092193 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $148.85 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691440227 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $48.40 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441451 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $60.50 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441537 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $36.30 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441787 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $22.62 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441814 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $29.70 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441893 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $47.25 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691442101 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $78.75 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691442199 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8.88 | 07/10/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691442205 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $474.00 | 07/05/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691469437 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,204.00 | 07/03/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691441063 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27,131.20 | 06/28/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691441439 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,646.00 | 06/26/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691350085 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $54,262.40 | 06/26/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | No dispute reported | 06/30/2026 | 691443571 |
| Principal investigator 1 | PFIZER INC. | $70,000.00 | 06/26/2019 | Non-covered Recipient Entity US Oncology Research LLC | TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE | No dispute reported | 06/30/2026 | 671656293 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,646.00 | 06/24/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691350081 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $14,066.40 | 06/21/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691350077 |
| Principal investigator 1 | PFIZER INC. | $2,965.00 | 06/18/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656375 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547299 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547301 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547303 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547305 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547307 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547309 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547311 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547315 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547317 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547319 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547321 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547323 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 06/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547325 |
| Principal investigator 1 | Incyte Corporation | $5,449.00 | 06/15/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations | No dispute reported | 06/30/2026 | 666480385 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,275.00 | 06/14/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691350089 |
| Principal investigator 1 | PFIZER INC. | $23,865.04 | 06/09/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUTAMIDE OR ABIRATERONE ACETATEPREDNISONE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER WITH DNA DAMAGE REPAIR DEFICIENCIES | No dispute reported | 06/30/2026 | 671656195 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $241.72 | 06/04/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691480423 |
| Principal investigator 1 | Genentech, Inc. | $979.50 | 05/30/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 681087515 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,863.45 | 05/30/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 691494627 |
| Principal investigator 1 | Genentech, Inc. | $4,510.50 | 05/23/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 681080293 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,348.80 | 05/22/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317133 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $614.00 | 05/21/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639760827 |
| Principal investigator 1 | PFIZER INC. | $1,496.82 | 05/14/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656127 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,239.36 | 05/13/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691439783 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10,826.24 | 05/09/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691439781 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $357.24 | 05/09/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691441443 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $43,304.96 | 05/09/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 691441447 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $783.60 | 05/09/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691443579 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $36.30 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691387693 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $13.60 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691388151 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $30.34 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691388329 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $47.25 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691388753 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $49.50 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691388907 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6.96 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691388909 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $83.00 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691397223 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12.10 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691414885 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $91.60 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691415999 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.80 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691416145 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $72.60 | 05/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691416799 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,093.51 | 05/07/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639760819 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,000.00 | 05/01/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639760821 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,066.90 | 04/26/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | No dispute reported | 06/30/2026 | 691480413 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15,651.80 | 04/24/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317039 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $21,704.96 | 04/23/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691441436 |
| Principal investigator 1 | Astellas Pharma Global Development | $140.00 | 04/18/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 641393189 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547173 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547175 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547177 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547179 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547181 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547183 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547185 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547187 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547189 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547191 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547193 |
| Principal investigator 1 | Eisai Inc. | $400.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547195 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547211 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547213 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547215 |
| Principal investigator 1 | Eisai Inc. | $400.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547227 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547229 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547231 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547233 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547235 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547237 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547239 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547241 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547243 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547245 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547247 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547249 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547251 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547253 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547255 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547257 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547259 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547261 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547263 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547265 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547267 |
| Principal investigator 1 | Eisai Inc. | $400.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547269 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547271 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547273 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547275 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547277 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547279 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547281 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547295 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547297 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 04/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $707.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $175.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $175.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255303 |
| Principal investigator 1 | Janssen Research & Development, LLC | $175.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $707.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $175.00 | 04/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255309 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,290.10 | 04/11/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na ve Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 691480419 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4,996.00 | 04/03/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317045 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,312.00 | 04/03/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317127 |
| Principal investigator 1 | Array BioPharma Inc. | $500.00 | 04/02/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870789 |
| Principal investigator 1 | Array BioPharma Inc. | $875.00 | 04/02/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870791 |
| Principal investigator 1 | Array BioPharma Inc. | $1,950.00 | 04/02/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870793 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,342.00 | 03/18/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317043 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,528.93 | 03/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Phase IIB Prostate Combos Doxetaxel PARP Enza | No dispute reported | 06/30/2026 | 639760845 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547197 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547199 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547201 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547203 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547205 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547207 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547209 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547217 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547219 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547221 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547223 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547225 |
| Principal investigator 1 | Eisai Inc. | $580.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547283 |
| Principal investigator 1 | Eisai Inc. | $2,130.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547285 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547287 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547289 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547291 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 03/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547293 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,246.14 | 03/12/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691289501 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $132.00 | 03/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691397595 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $21,541.00 | 03/06/2019 | Non-covered Recipient Entity Us Oncology Res Llc | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 | No dispute reported | 06/30/2026 | 639760843 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $21,723.04 | 03/06/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST P.C. | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) inSubjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive toBacillus Calmette-Guerin (BCG) Therapy | No dispute reported | 06/30/2026 | 691289391 |
| Principal investigator 1 | PFIZER INC. | $1,561.66 | 03/05/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656125 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,756.40 | 02/25/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691317200 |
| Principal investigator 1 | PFIZER INC. | $1,014.55 | 02/20/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656295 |
| Principal investigator 1 | Eisai Inc. | $980.00 | 02/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547167 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 02/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547169 |
| Principal investigator 1 | Eisai Inc. | $1,200.00 | 02/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547171 |
| Principal investigator 1 | Array BioPharma Inc. | $425.00 | 02/14/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870785 |
| Principal investigator 1 | Array BioPharma Inc. | $325.00 | 02/14/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870787 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,462.00 | 02/14/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 641393185 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $67,500.00 | 02/13/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase 1b Dose Escalation Study to Assess the Safety of AFM13in Combination with Pembrolizumab in Patients with Relapsedor Refractory Classical Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 691312649 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $1,231.20 | 02/07/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | PCYC-1128-CA | No dispute reported | 06/30/2026 | 673091605 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $29,267.00 | 02/06/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every | No dispute reported | 06/30/2026 | 639760835 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $554.40 | 02/04/2019 | Non-covered Recipient Entity Us Oncology Reserch Llc | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | No dispute reported | 06/30/2026 | 629160211 |
| Principal investigator 1 | PFIZER INC. | $6,625.16 | 02/02/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656297 |
| Principal investigator 1 | Novocure Inc. | $1,800.00 | 01/31/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. Nebraska Cancer Specialists | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. | No dispute reported | 06/30/2026 | 694525957 |
| Principal investigator 1 | Novocure Inc. | $1,573.00 | 01/31/2019 | Non-covered Recipient Entity Oncology Hematology West, P.C. Nebraska Cancer Specialists | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. | No dispute reported | 06/30/2026 | 694525959 |
| Principal investigator 1 | Dynavax Technologies Corporation | $2,689.00 | 01/28/2019 | Non-covered Recipient Entity Oncology Hematology West | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 696040877 |
| Principal investigator 1 | Array BioPharma Inc. | $625.00 | 01/24/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870783 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,510.50 | 01/24/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639760831 |
| Principal investigator 1 | TESARO, Inc. | $13,518.08 | 01/24/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A PHASE III TRIAL OF NIRAPARIB VERSUS PHYSICIAN'S CHOICE IN HER2 NEGATIVE, GERMLINE BRCA MUTATION-POSITIVE BREAST CANCER PATIENTS BRAVO | No dispute reported | 06/30/2026 | 689409841 |
| Principal investigator 1 | PFIZER INC. | $3,305.48 | 01/23/2019 | Non-covered Recipient Entity Oncology Hematology West PC dba Nebraska Cancer Specialists | A STUDY OF AVELUMAB IN COMBINATION WITH AXITINIB IN NONSMALL CELL LUNG CANCER NSCLC OR UROTHELIAL CANCER JAVELIN MEDLEY VEGF | No dispute reported | 06/30/2026 | 671656207 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $14,492.40 | 01/21/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691309315 |
| Principal investigator 1 | Array BioPharma Inc. | $600.00 | 01/15/2019 | Covered Recipient Teaching Hospital NEBRASKA METHODIST HOSPITAL | A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors | No dispute reported | 06/30/2026 | 704870781 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,400.00 | 01/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | SUSTAIN, event driven trial | No dispute reported | 06/30/2026 | 639760825 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,894.00 | 01/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Nivo RCC Safety Trial | No dispute reported | 06/30/2026 | 639760833 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,757.00 | 01/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Nivo Dose Frequency Optimization Lung Trial | No dispute reported | 06/30/2026 | 639760839 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $21,648.00 | 01/15/2019 | Non-covered Recipient Entity Nebraska Cancer Specialists | Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway | No dispute reported | 06/30/2026 | 639760841 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547135 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547137 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547139 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547141 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547143 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547145 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547147 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547149 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547151 |
| Principal investigator 1 | Eisai Inc. | $565.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547153 |
| Principal investigator 1 | Eisai Inc. | $899.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547155 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547157 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547159 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547161 |
| Principal investigator 1 | Eisai Inc. | $450.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547163 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 01/15/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 702547165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $707.00 | 01/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $707.00 | 01/15/2019 | Non-covered Recipient Entity Oncology Hematlgy W PC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 654255297 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $146.52 | 01/15/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETINIB VERSUS PLACEBO DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA | No dispute reported | 06/30/2026 | 640721671 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $49,413.00 | 01/14/2019 | Non-covered Recipient Entity Us Oncology Res Llc | Phase IIB Prostate Combos PARP Enza Chemo | No dispute reported | 06/30/2026 | 639760851 |
| Principal investigator 1 | Eli Lilly and Company | $5,000.00 | 01/14/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 | No dispute reported | 06/30/2026 | 654299343 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $371.54 | 01/11/2019 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC | No dispute reported | 06/30/2026 | 691480425 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $21,661.52 | 01/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691289504 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,312.00 | 01/08/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy | No dispute reported | 06/30/2026 | 691309317 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,821.52 | 01/01/2019 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY | TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING | No dispute reported | 06/30/2026 | 640723123 |